MicroRNA-210在肺癌中诊断价值的荟萃分析及系统评价
发布时间：2018-10-18 17:56
【摘要】：目的:通过对现有micro RNA-210在肺癌中诊断价值的研究进行系统综述和荟萃分析,探讨micro RNA-210对肺癌的诊断价值。方法:在Pubmed、Embase、Web of Knowledge、Cochrane Library、CNKI、维普和万方数据库中全面检索文献,按照纳入及排除标准筛选出合格文献,根据QUADAS-2评价文献质量并提取所需数据,使用Stata 12.0和Meta-disc 1.4进行统计分析,应用双变量随机混合效应模型得出合并诊断值,并进一步应用层次综合受试者工作特征曲线(HSROC)验证上述结果。此外,评估各研究间异质性和发表偏倚。结果:本项meta分析最终纳入9篇文献,共包括993例样本(554例肺癌患者和439例非肺癌对照)。应用双变量随机混合效应模型经统计分析得出,micro RNA-210对肺癌诊断的合并灵敏度、特异度、阳性似然比、阴性似然比及诊断比值比分别为0.66(95%CI:0.57~0.75),0.82(95%CI:0.72~0.89),3.64(95%CI:2.54~5.21),0.41(95%CI:0.34~0.51),8.78(95%CI:6.10~12.66)。拟合受试者工作曲线的曲线下面积为0.80(95%CI:0.76~0.83)。此外,HSROC曲线显示SROC曲线对称,?值为2.08(95%CI:1.76~2.40),HSROC模型同样表明micro RNA-210在肺癌中诊断价值中等。由于各文献间存在异质性,进行meta回归分析和亚组分析探索可能的异质性来源,结果显示,国家、肿瘤分期、肺癌类型、样本种类和内参等变量均不是异质性来源。Deeks’漏斗图显示各研究无发表偏倚,Spearman等级相关检验显示不存在阈值效应。结论:Micro RNA-210在肺癌中诊断价值中等,仍需更多前瞻性研究进一步证实micro RNA-210在肺癌中的诊断价值。
[Abstract]:Objective: to study the diagnostic value of micro RNA-210 in lung cancer by systematic review and meta-analysis. Methods: the literature was searched in the database of Pubmed,Embase,Web of Knowledge,Cochrane Library,CNKI, Weip and Wanfang, and qualified literature was screened according to the inclusion and exclusion criteria. The quality of literature was evaluated according to QUADAS-2 and the required data were extracted. Stata 12.0 and Meta-disc 1.4 were used for statistical analysis. The combined diagnostic value was obtained by using the two-variable random mixing effect model, and the above results were verified by the hierarchical synthetic operating characteristic curve (HSROC). In addition, heterogeneity and publication bias among studies were assessed. Results: this meta analysis included 9 articles, including 993 samples (554 lung cancer patients and 439 non-lung cancer controls). The combined sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic ratio of micro RNA-210 for lung cancer were 0.66 (95%CI:0.57~0.75), 0.82 (95%CI:0.72~0.89), 3.64 (95%CI:2.54~5.21), 0.41 (95%CI:0.34~0.51), 8.78 (95%CI:6.10~12.66), respectively. The area under the curve fitted to the operating curve was 0. 80 (95%CI:0.76~0.83). In addition, the HSROC curve shows the symmetry of the SROC curve,? The value of micro RNA-210 was 2.08 (95%CI:1.76~2.40), HSROC model also showed that micro RNA-210 was of moderate value in the diagnosis of lung cancer. Due to the heterogeneity in various literatures, meta regression analysis and subgroup analysis were carried out to explore the possible sources of heterogeneity. The results showed that country, tumor stage, lung cancer type, Deeks' funnel graph showed that there was no publication bias in each study, and Spearman grade correlation test showed that there was no threshold effect. Conclusion: the diagnostic value of Micro RNA-210 in lung cancer is moderate, and more prospective studies are needed to further confirm the diagnostic value of micro RNA-210 in lung cancer.
【学位授予单位】：首都医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R734.2
，
本文编号：2279920
[Abstract]:Objective: to study the diagnostic value of micro RNA-210 in lung cancer by systematic review and meta-analysis. Methods: the literature was searched in the database of Pubmed,Embase,Web of Knowledge,Cochrane Library,CNKI, Weip and Wanfang, and qualified literature was screened according to the inclusion and exclusion criteria. The quality of literature was evaluated according to QUADAS-2 and the required data were extracted. Stata 12.0 and Meta-disc 1.4 were used for statistical analysis. The combined diagnostic value was obtained by using the two-variable random mixing effect model, and the above results were verified by the hierarchical synthetic operating characteristic curve (HSROC). In addition, heterogeneity and publication bias among studies were assessed. Results: this meta analysis included 9 articles, including 993 samples (554 lung cancer patients and 439 non-lung cancer controls). The combined sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic ratio of micro RNA-210 for lung cancer were 0.66 (95%CI:0.57~0.75), 0.82 (95%CI:0.72~0.89), 3.64 (95%CI:2.54~5.21), 0.41 (95%CI:0.34~0.51), 8.78 (95%CI:6.10~12.66), respectively. The area under the curve fitted to the operating curve was 0. 80 (95%CI:0.76~0.83). In addition, the HSROC curve shows the symmetry of the SROC curve,? The value of micro RNA-210 was 2.08 (95%CI:1.76~2.40), HSROC model also showed that micro RNA-210 was of moderate value in the diagnosis of lung cancer. Due to the heterogeneity in various literatures, meta regression analysis and subgroup analysis were carried out to explore the possible sources of heterogeneity. The results showed that country, tumor stage, lung cancer type, Deeks' funnel graph showed that there was no publication bias in each study, and Spearman grade correlation test showed that there was no threshold effect. Conclusion: the diagnostic value of Micro RNA-210 in lung cancer is moderate, and more prospective studies are needed to further confirm the diagnostic value of micro RNA-210 in lung cancer.
【学位授予单位】：首都医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R734.2
，
本文编号：2279920
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2279920.html
